WO2021017834A1 - Composition cutanée à usage externe ayant un effet anti-inflammatoire - Google Patents

Composition cutanée à usage externe ayant un effet anti-inflammatoire Download PDF

Info

Publication number
WO2021017834A1
WO2021017834A1 PCT/CN2020/102178 CN2020102178W WO2021017834A1 WO 2021017834 A1 WO2021017834 A1 WO 2021017834A1 CN 2020102178 W CN2020102178 W CN 2020102178W WO 2021017834 A1 WO2021017834 A1 WO 2021017834A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
birch sap
skin
concentration
external
Prior art date
Application number
PCT/CN2020/102178
Other languages
English (en)
Chinese (zh)
Inventor
王莎莎
Original Assignee
浙江养生堂天然药物研究所有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江养生堂天然药物研究所有限公司 filed Critical 浙江养生堂天然药物研究所有限公司
Publication of WO2021017834A1 publication Critical patent/WO2021017834A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to an external skin composition with anti-inflammatory effects, which comprises concentrated birch tree sap with a concentration factor of about 1.05-8 times, preferably about 1.1-4 times.
  • the external skin composition includes a pharmaceutical composition and a cosmetic composition, especially a skin care cosmetic composition.
  • Birch sap is the sap that flows from the birch family plant. It is rich in polysaccharides, amino acids, vitamins, biotin, cytokinins, minerals, etc. that the human body needs. It has good anti-inflammatory and soothing effects and can inhibit various causes. (Including the external temperature is too cold and hot, ultraviolet radiation, detergent irritation, bacteria and viruses and other microorganisms whatsoever of the skin, etc.) skin erythema, edema, tingling, fever, itching, vasodilation problems.
  • the present invention relates to a concentrated birch sap with a concentration factor of about 1.05-8 times, preferably about 1.1-4 times.
  • the present invention relates to the use of concentrated birch tree juice in a skin external composition with anti-inflammatory effects, wherein the concentration factor of the concentrated birch tree juice is about 1.05-8 times, preferably about 1.1-4 times.
  • the present invention relates to a skin topical composition with anti-inflammatory effect, which comprises (A) concentrated birch sap with a concentration factor of about 1.05-8 times, preferably about 1.1-4 times.
  • the external skin composition includes a pharmaceutical composition and a cosmetic composition, especially a skin care cosmetic composition.
  • the birch sap involved in the present invention is obtained from the genus Betula, Betula alba, Betula pubescens, Betula Pendula and Asian white birch (Betula platyphylla). Varieties.
  • the birch sap is a colorless, transparent, no-sediment-free, and no-drug sap that is artificially collected by drilling holes at the base of the trunk of the birch from thawing to early spring.
  • the birch sap is commercially available and used as it is, for example, it can be purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd.
  • the concentrated birch sap in the present invention is obtained by concentrating the above-mentioned commercial products. Concentration methods are known in the art, such as heating concentration, low-temperature vacuum concentration, membrane concentration and the like. In the present invention, the concentration is preferably carried out by a low-temperature freeze concentration or membrane concentration process. For example, the commercially available birch juice stock solution is input into a low-temperature drying equipment, the temperature is lowered to -40°C to -70°C, and the vacuum is applied to 0.1-30Pa. Concentrated in vacuum at low temperature to obtain concentrated birch sap with different concentration times.
  • concentrated birch sap has significantly better anti-inflammatory effects, which can effectively protect mast cells, inhibit the release of inflammatory mediators, and relieve Skin erythema, edema, irritation, fever, itching, vasodilation caused by various reasons (including external temperature too cold and overheating, ultraviolet radiation, detergent stimulation, bacterial virus and other microorganisms persecuting the skin, etc.), repair fragile skin , Strengthen the skin barrier, soothe and treat sensitive skin.
  • controlling the concentration ratio of birch sap is critical.
  • controlling the concentration ratio of birch sap is about 1.05-8 times, preferably about 1.1-4 times.
  • the external skin composition of the present invention does not contain chelating agents such as EDTA salt, sodium polyphosphate, sodium metaphosphate, and gluconic acid.
  • chelating agents such as EDTA salt, sodium polyphosphate, sodium metaphosphate, and gluconic acid.
  • the skin external composition of the present invention does not contain any added water, but does not exclude moisture inherently contained in each component.
  • the content of the (A) concentrated birch sap may be about 18-98% by weight, preferably 20-95% by weight, more preferably 22-90% by weight, most preferably 30-90% by weight, based on the skin external composition The total weight.
  • the external skin composition may optionally contain (B) ingredients commonly used in skin external compositions, especially ingredients commonly used in skin care cosmetic compositions.
  • the common ingredients are known in the art, and include, for example, vehicles, active ingredients, and auxiliary materials.
  • Those skilled in the art can select the type and amount of component (B) according to needs. For example, the content of component (B) is about 2-82% by weight, based on the total weight of the skin external composition.
  • the vehicle is known in the art and includes, for example, a diluent, a dispersant, or a carrier. Examples thereof include, but are not limited to, ethanol, dipropylene glycol, butylene glycol and the like.
  • the content of the vehicle in the skin topical composition is known in the art, for example, it usually accounts for 0.5-20% of the total weight of component (B).
  • the active ingredients are known in the art and include, for example, emollients, moisturizers, anti-inflammatory active ingredients and the like.
  • emollient examples include, but are not limited to, olive oil, macadamia nut oil, sweet almond oil, grape seed oil, avocado oil, corn oil, sesame oil, soybean oil, peanut oil, white flower seed oil, safflower seed oil, Dogtooth rose hip oil, argan tree kernel oil, jojoba seed oil, sunflower seed oil, palm tree fruit oil, squalane, ethylhexyl palmitate, isopropyl myristate, hydrogenated polyisobutylene, isotene Hexane, isododecane, diethylhexyl carbonate, dioctyl carbonate, isopropyl lauroyl sarcosine, isononyl isononanoate, hydrogenated polydecene, glycerol tri(ethylhexanoate) , Cetyl alcohol ethyl hexanoate, bis-diethoxy diethylene glycol cyclohexane
  • solid emollients include, but are not limited to, cetyl alcohol, stearyl alcohol, cetearyl alcohol, behenyl alcohol, scylitol, lauric acid, myristic acid, palmitic acid, stearic acid, beeswax, candelilla Tree wax, carnauba wax, lanolin, ozokerite, jojoba seed wax, paraffin wax, microcrystalline wax, hydrogenated rice bran wax, hydrogenated coconut oil glycerides, glyceryl behenate/eicosanate, myristyl alcohol One or more of myristate, bis-diglyceride polyacyl adipate-2, shea butter, and muluxing palm seed butter.
  • the content of the emollient in the external skin composition is known in the art, for example, it usually accounts for 1-50% of the total weight of the component (B).
  • moisturizer examples include, but are not limited to, glycerin, diglycerin, butylene glycol, propylene glycol, 1,3-propanediol, dipropylene glycol, 1,2-pentanediol, polyethylene glycol-8, polyethylene glycol Alcohol-32, methylglucitol-10, methylglucitol-20, PEG/PPG-17/6 copolymer, glycerol-7, glycerol-26, glycerol glucoside, PPG-10 methyl glucose ether, PPG-20 methyl glucose ether, PEG/PPG/polybutylene glycol-8/5/3 glycerin, sucrose, trehalose, rhamnose, mannose, raffinose, Betaine, erythritol, xylitol, urea, glyceryl polyether-5 lactate, sodium hyaluronate, hydrolyzed sodium hyaluronate, acetyl
  • anti-inflammatory active ingredients include, but are not limited to, dipotassium glycyrrhizinate, portulaca (PORTULACA OLERACEA) extract, oat (AVENA SATIVA) kernel extract (oatyl anthranilic acid), panthenol, allantoin , Biological sugar gum-1, ⁇ -glucan, fructan, SCUTELLARIA BAICALENSIS root extract, Aesculus HIPPOCASTANUM extract, bisabolol, 4-tert-butyl cyclohexanol, nerve Amide 3, hydrogenated lecithin, licorice root (GLYCYRRHIZA GLABRA) extract, hydrolyzed royal jelly protein, oryzanol, phytosphingosine, quercetin (quercetin), ginger root extract, rosemary leaf extract, white flower One or more of chamomile extract, calendula extract, centella asiatica extract, naringin, hesperidin, etc.
  • the anti-inflammatory active ingredient may also be one or more of glucocorticoids or calcineurin inhibitors, such as cortisone, erythromycin, mometasone furoate, fluticasone propionate, tacrolimus , Pimecrolimus and so on.
  • the content of the anti-inflammatory active ingredient in the skin external composition is known in the art, for example, it usually accounts for 0.01-10% of the total weight of the component (B).
  • auxiliary materials include, for example, emulsifiers, thickeners, preservatives, perfumes and the like.
  • emulsifier examples include, but are not limited to, cetearyl oleate, sorbitan oleate, polysorbate-60, polysorbate-80, methylglucose sesquistearic acid Ester, PEG-20 methyl glucose sesquistearate, PEG-40 hydrogenated castor oil, PPG-26-butanol-26, PEG-4 polyglycerol-2 stearate, PEG-60 hydrogenated Castor oil, steareth-2, steareth-21, PPG-13-decyltetradeceth-24, cetearyl glucoside, PEG-100 stearate, glycerin Stearate, Glyceryl Stearate SE, Coco Glucoside, Ceteareth-25, PEG-40 Stearate, Polyglyceryl-3 Methyl Glucose Distearate, Glyceryl stearate citrate, polyglyceryl-10 stearate, polyglyceryl-10 myristate, polyglyce
  • the thickener examples include, but are not limited to, carbomers, acrylic acid (ester) and its derivatives, xanthan gum, gum arabic, polyethylene glycol-14M, polyethylene glycol-90M, succinyl poly One or more of high molecular polymers such as sugar, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.
  • the content of the thickener in the external skin composition is known in the art, for example, it usually accounts for 0.1-10% of the total weight of the component (B).
  • preservatives examples include, but are not limited to, methylparaben, propylparaben, phenoxyethanol, benzyl alcohol, phenethyl alcohol, bis(hydroxymethyl)imidazolidinylurea, potassium sorbate, sodium benzoate, chlorobenzene Glycerol, sodium dehydroacetate, caprylic hydroxamic acid, 1,2-hexanediol, 1,2-pentanediol, p-hydroxyacetophenone, caprylyl glycol, glyceryl caprylate, undecylenic acid
  • the content of the preservative in the external skin composition is known in the art, for example, it usually accounts for 0.01-2% of the total weight of the component (B).
  • the skin external composition of the present invention can be prepared by any suitable method known in the art.
  • it can be prepared by dissolving tanks, emulsifying pots, dispersers, and delivery pumps commonly used in the cosmetics field.
  • dissolving tanks emulsifying pots, dispersers, and delivery pumps commonly used in the cosmetics field.
  • When preparing put the water-soluble substance into the water-phase dissolving kettle, and the oil-soluble substance into the oil-phase dissolving kettle, and heat the temperature of the two kettles to about 80°C.
  • the raw materials that are easy to agglomerate they can be mixed with a disperser first. Pre-dispersion. After the dissolution is completed, the oil phase and the water phase are transported to the emulsifying pot for homogenization and emulsification for about 5-15 minutes.
  • the temperature of the material body is reduced to normal temperature, optional flavors, preservatives, etc. are added, and the pH of the product is adjusted as necessary.
  • the products can be filled and shipped only after the relevant test indicators are qualified.
  • the above preparation methods can be deleted or adjusted according to dosage form requirements.
  • the external skin composition of the present invention may be a pharmaceutical composition or a cosmetic composition, especially a cosmetic composition.
  • the cosmetic composition can be in various dosage forms such as lotion, spray, lotion, cream, cream or gel.
  • Example 1 The effect of birch sap stock and concentrated birch sap on histamine release from RBL-2H3 cells
  • the fresh white birch sap stock purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd. is fed into low-temperature drying equipment, cooled to -65°C, vacuumed to 0.1Pa, and concentrated to 1.05 times, 1.1 times, 1.2 times, 1.5 times, and 2 Times, 4 times, 8 times.
  • Compound 48/80 (a G protein activator) is a tool drug that causes degranulation of mast cells. Its mechanism is to act on the mast cell membrane, causing an increase in intracellular calcium ions, thereby increasing the amount of second messengers cAMP and cGMP Changes occur, causing mast cells to degranulate and release histamine.
  • the cell line RBL-2H3 was provided by the Animal Center of Zhejiang Academy of Medical Sciences; the test samples included 6 sample compositions to be tested, and the reagents included fetal bovine serum, Tyrode's salt, compound 48/80, and histamine Elisa kit.
  • Compound 48/80 solution preparation Weigh 1.0mg of 48/80 powder, dilute with 1mL Tyrode's solution, take 50uL and dilute to 1000uL, that is, a 48/80 solution with a concentration of 50ug/mL, which needs to be prepared for immediate use .
  • Model group Take 700uL cell suspension centrifugation and resuspend it in background solution, and place it at 37°C for 30 minutes.
  • Sample group Take 700uL cell suspension centrifugation and resuspend the sample solution, and place it at 37°C for 30 minutes.
  • each tube is 200uL; model group and 6 sample groups: add 50uL of 48/80 solution to the cell suspension, the final concentration is 10ug/mL, and place it at 37°C for 20 minutes. 3 repetitions per group.
  • Histamine determination Put the samples of the above groups in an ice box to cool for 10 minutes to stop the reaction. Centrifuge the sample after termination of the reaction (4°C, 1500 rpm, 30 minutes) to allow the cells to settle on the bottom of the EP tube, and transfer the supernatant to a new centrifuge tube. Resuspend the precipitated cells with 250 ⁇ L of 1x Tyrode's solution, put them in a 90°C water bath for heating, take it out 5 minutes later, immediately put it in the ice box, wait for the sample to cool down completely, take it out, put it in a 90°C water bath to heat again, repeat Freeze and thaw several times to break the cells. The supernatant and cell fluid were diluted 10-fold, and the stock solution was stored in a refrigerator at -20°C. The diluted sample is determined and calculated with an imported histamine kit for histamine determination. The calculation formula of histamine release rate is:
  • Example 2 The effect of birch sap stock and concentrated birch sap on the degranulation of zebrafish mast cells
  • the fresh white birch sap stock purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd. is fed into low-temperature drying equipment, cooled to -65°C, vacuumed to 0.1Pa, and concentrated to 1.05 times, 1.1 times, 1.2 times, 1.5 times, and 2 Times, 4 times, 8 times.
  • Test animal zebrafish 5 days after fertilization (5dpf)
  • Sample group to be tested birch sap stock solution and birch sap with different concentration times + 15 ⁇ g/ml SP.
  • Example 3 The effect of birch sap stock and concentrated birch sap on the model of irritant contact dermatitis in mice
  • the fresh birch sap stock solution purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd. is fed into the reverse osmosis circulation device, the operating pressure is controlled at 0.5-5bar, and the operating temperature is controlled at 20-35°C, and circulated until the birch sap is respectively concentrated to 1.1 Times, 1.2 times, 1.5 times, 2 times, 4 times.
  • Test animal ICR mouse, male
  • Test reagents 10% sodium dodecyl sulfate solution (SDS), 1% hydrocortisone ointment, depilatory cream
  • mice were randomly grouped according to their body weight, each with 12 mice, divided into normal group, model group, positive group, and each sample group to be tested. All mice used depilatory cream to remove the skin and hair of about 2*2cm area on the mouse abdomen. No other treatments were done for the normal group.
  • the model group, the positive group, and each sample group to be tested were applied with 10% sodium lauryl sulfate solution for 5 consecutive days to complete the modeling. After modeling, the positive group was smeared with 1% hydrocortisone ointment 3 times a day for 2 consecutive days; the model group was not treated; each sample group to be tested was sprayed with the corresponding mixed birch sap, 3 times a day, 2 consecutive days day. On the 7th day of the experiment, the skin conditions of the experimental mice in each group were observed, and the serum of the mice was taken to determine the content of inflammatory factor IL-1a.
  • Example 4 The effect of birch sap stock and concentrated birch sap on mice models of allergic contact dermatitis
  • the fresh birch sap stock solution purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd. is fed into the reverse osmosis circulation device, the operating pressure is controlled at 0.5-5bar, and the operating temperature is controlled at 20-35°C, and circulated until the birch sap is respectively concentrated to 1.1 Times, 1.2 times, 1.5 times, 2 times, 4 times.
  • Test animal ICR mouse, male
  • Investigation indicators ear thickness index, ear weight, inflammation index interferon- ⁇ (IFN- ⁇ ), interleukin-4 (IL-4)
  • Test materials 1% 2,4-dinitrofluorobenzene (DNFB) acetone olive oil solution (4:1), 1% hydrocortisone ointment, depilatory cream
  • mice were randomly grouped according to their body weight, each with 12 mice, divided into normal group, model group, positive group, and each sample group to be tested.
  • Each group of experimental mice used depilatory cream to remove the skin and hair in the abdomen area of about 2*2cm.
  • the abdomen and ears of mice in the normal group were evenly coated with acetone olive oil solution for control.
  • Mice in the model group, positive group, and each sample group to be tested were smeared with 1% DNFB-containing acetone olive oil solution for sensitization and stimulation to establish a mouse model of allergic contact dermatitis.
  • model group After being challenged, the model group was sprayed with distilled water; the positive group was sprayed with 1% hydrocortisone ointment for 2 consecutive days, 3 times/day; each sample group to be tested was sprayed with the corresponding mixed birch sap, 3 times a day, continuous administration 2 days.
  • anti-inflammatory spray composition is prepared as follows:
  • VISIA-CR Using VISIA-CR to collect the facial images of volunteers under the condition of using front and rear polarized light, and use IPP software to analyze the erythema area of the same measurement area at different test time points on the left and right cheeks of volunteers.
  • the formula of the anti-inflammatory cream composition is shown in the following table:
  • the aforementioned anti-inflammatory cream composition is prepared as follows:
  • Oil phase Add raw materials 4, 6, 7, 8, 9, 11, 12, 13, and 15 to the oil phase pot, and heat to 80°C, dissolve, and mix well;
  • Emulsification add the water phase and the oil phase to the emulsification tank, keep it at 80°C, homogenize emulsification at 3000rpm for 5 minutes, add No. 19 raw material after emulsification is complete;
  • step 3 The mixture of step 3 is added when the temperature is lowered to 40°C by stirring, and the mixture is uniformly stirred and discharged to obtain the anti-inflammatory facial cream composition.
  • Example 6 Anti-inflammatory emulsion composition
  • the anti-inflammatory emulsion composition described above is prepared as follows:
  • Oil phase add No. 4, 5, 6, 7, 12, 13 raw materials into the oil phase pot, and heat to 80°C, dissolve, and mix well;
  • Emulsification add the water phase and the oil phase to the emulsification tank, keep the temperature at 80°C, homogenize and emulsify for 5 minutes at 3000 rpm, and add No. 15 raw material after the emulsification is completed;
  • step 6 Add the mixture of step 3 when stirring and cooling down to 40°C, stir evenly and then discharge to obtain the anti-inflammatory emulsion composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition cutanée à usage externe ayant un effet anti-inflammatoire, comprenant de la sève de bouleau concentrée, avec un facteur de concentration compris entre 1,05 et 8, de préférence entre 1,1 et 4.
PCT/CN2020/102178 2019-07-30 2020-07-15 Composition cutanée à usage externe ayant un effet anti-inflammatoire WO2021017834A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910693912.4A CN110731973A (zh) 2019-07-30 2019-07-30 具有抗炎功效的皮肤外用组合物
CN201910693912.4 2019-07-30

Publications (1)

Publication Number Publication Date
WO2021017834A1 true WO2021017834A1 (fr) 2021-02-04

Family

ID=69267660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/102178 WO2021017834A1 (fr) 2019-07-30 2020-07-15 Composition cutanée à usage externe ayant un effet anti-inflammatoire

Country Status (2)

Country Link
CN (1) CN110731973A (fr)
WO (1) WO2021017834A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110731976B (zh) * 2019-07-30 2024-02-06 浙江养生堂天然药物研究所有限公司 防脱生发组合物
CN110731973A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 具有抗炎功效的皮肤外用组合物
CN110731925A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 美白化妆品组合物
CN110876760B (zh) * 2019-11-28 2022-09-30 浙江养生堂天然药物研究所有限公司 具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物
CN115998671A (zh) * 2021-10-23 2023-04-25 北京嘉桦生物技术有限公司 一种温敏型原位凝胶在烧烫伤皮肤修复中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909586A (zh) * 2007-12-27 2010-12-08 花王株式会社 粉刺肌肤用皮肤外用剂
CN110731928A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 抗衰老化妆品组合物
CN110731925A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 美白化妆品组合物
CN110731921A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 具有祛痘功效的皮肤外用组合物
CN110731973A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 具有抗炎功效的皮肤外用组合物
CN110731976A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 防脱生发组合物
CN110731929A (zh) * 2019-08-21 2020-01-31 浙江养生堂天然药物研究所有限公司 混合的桦树汁及其在护肤化妆品组合物中的应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909586A (zh) * 2007-12-27 2010-12-08 花王株式会社 粉刺肌肤用皮肤外用剂
CN110731928A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 抗衰老化妆品组合物
CN110731925A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 美白化妆品组合物
CN110731921A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 具有祛痘功效的皮肤外用组合物
CN110731973A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 具有抗炎功效的皮肤外用组合物
CN110731976A (zh) * 2019-07-30 2020-01-31 浙江养生堂天然药物研究所有限公司 防脱生发组合物
CN110731929A (zh) * 2019-08-21 2020-01-31 浙江养生堂天然药物研究所有限公司 混合的桦树汁及其在护肤化妆品组合物中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARBER VAL, JULIE CASCIO: "Birch Tree Tapping", 30 October 2002 (2002-10-30), pages 1 - 16, XP055776295, Retrieved from the Internet <URL:http://www.hackteria.org/wordpress/wp-content/uploads/2012/04/Birch-Tree-Tapping.pdf> *
HUI, QINGJIE ET AL: "Birch Sap Cosmetics", CHINA SURFACTANT DETERGENT & COSMETICS, no. 4, 31 December 1990 (1990-12-31), pages 55, 51, XP009525686, DOI: 10.13218/j.cnki.csdc.1990.04.017 *
JIANG, DESEN ET AL: "Study on Concentration of Birch Sap", JOURNAL OF JILIN FORESTRY UNIVERSITY, vol. 5, no. 2, 30 April 1989 (1989-04-30), pages 63 - 70, XP009525687, ISSN: 1004-6992 *
JIANG, ZHONGHAI: "Study on the Birch Juice in Heilongjiang", SCIENCE AND TECHNOLOGY OF FOOD INDUSTRY, vol. 23, no. 10, 31 October 2002 (2002-10-31), pages 62 - 63, XP009525685, ISSN: 1002-0306 *

Also Published As

Publication number Publication date
CN110731973A (zh) 2020-01-31

Similar Documents

Publication Publication Date Title
WO2021017834A1 (fr) Composition cutanée à usage externe ayant un effet anti-inflammatoire
WO2018196482A1 (fr) Composition cosmétique pour le soin de la peau
WO2018196481A1 (fr) Composition de produit cosmétique hydratant
WO2021017910A1 (fr) Composition de traitement de la peau externe ayant un effet anti-inflammatoire amélioré
WO2021017846A1 (fr) Composition cosmétique anti-âge améliorée
WO2021031750A1 (fr) Sève de bouleau mélangée et son application dans une composition cosmétique de soin de la peau
WO2021017833A1 (fr) Composition cosmétique anti-âge
JP7422214B2 (ja) 抗ざ瘡有効性を有する皮膚局所用組成物
WO2021017911A1 (fr) Composition améliorée de prévention de chute de cheveux et de promotion de la pousse des cheveux
IL260028B1 (en) Baby care products
WO2021017838A1 (fr) Composition topique pour la peau à effet anti-eczéma
CN108670878B (zh) 抗皮肤过敏的化妆品组合物
WO2021017913A1 (fr) Composition cosmétique à rétention d&#39;humidité améliorée
EP2395966B1 (fr) Préparation cosmétique pour le soin de la peau
US20220218595A1 (en) Method of using soothing cream including maca root extract as an active ingredient
CN113197836A (zh) 一种保湿舒缓止痒护肤乳霜及其制备方法
WO2021017844A1 (fr) Composition externe pour la peau à effet anti-eczéma amélioré
WO2021017878A1 (fr) Composition ayant un effet d&#39;élimination de l&#39;acné pour application externe sur la peau
WO2021017912A1 (fr) Composition cosmétique hydratante
CN114632049B (zh) 一种防脱生发组合物
WO2021017845A1 (fr) Composition pour la pousse des cheveux contre la chute des cheveux
CN112842952B (zh) 酵母菌发酵的桦树汁及其在防脱生发组合物中的应用
JP4674286B2 (ja) 乳化剤及び化粧料
WO2021017448A1 (fr) Composition externe pour la peau destinée à soulager les démangeaisons
KR101410042B1 (ko) 프로폴리스 나노 베시클을 함유하는 보습화장품 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20848593

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20848593

Country of ref document: EP

Kind code of ref document: A1